Dogwood Therapeutics (DWTX) Competitors $3.73 -0.43 (-10.34%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock DWTX vs. CGTX, FNCH, OVID, LGVN, PULM, RVPH, MURA, NAII, ENLV, and PMNShould you be buying Dogwood Therapeutics stock or one of its competitors? The main competitors of Dogwood Therapeutics include Cognition Therapeutics (CGTX), Finch Therapeutics Group (FNCH), Ovid Therapeutics (OVID), Longeveron (LGVN), Pulmatrix (PULM), Reviva Pharmaceuticals (RVPH), Mural Oncology (MURA), Natural Alternatives International (NAII), Enlivex Therapeutics (ENLV), and ProMIS Neurosciences (PMN). These companies are all part of the "pharmaceutical products" industry. Dogwood Therapeutics vs. Cognition Therapeutics Finch Therapeutics Group Ovid Therapeutics Longeveron Pulmatrix Reviva Pharmaceuticals Mural Oncology Natural Alternatives International Enlivex Therapeutics ProMIS Neurosciences Dogwood Therapeutics (NASDAQ:DWTX) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation, dividends and community ranking. Do insiders & institutionals believe in DWTX or CGTX? 9.1% of Dogwood Therapeutics shares are held by institutional investors. Comparatively, 43.3% of Cognition Therapeutics shares are held by institutional investors. 12.2% of Dogwood Therapeutics shares are held by company insiders. Comparatively, 20.8% of Cognition Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more volatility & risk, DWTX or CGTX? Dogwood Therapeutics has a beta of 1.99, indicating that its stock price is 99% more volatile than the S&P 500. Comparatively, Cognition Therapeutics has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Does the MarketBeat Community believe in DWTX or CGTX? Cognition Therapeutics received 24 more outperform votes than Dogwood Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformDogwood TherapeuticsN/AN/ACognition TherapeuticsOutperform Votes2472.73% Underperform Votes927.27% Which has higher valuation & earnings, DWTX or CGTX? Cognition Therapeutics is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDogwood TherapeuticsN/AN/A-$5.30M-$11.34-0.33Cognition TherapeuticsN/AN/A-$25.79M-$0.87-0.43 Do analysts prefer DWTX or CGTX? Cognition Therapeutics has a consensus price target of $7.13, indicating a potential upside of 1,809.16%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cognition Therapeutics is more favorable than Dogwood Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dogwood Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cognition Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is DWTX or CGTX more profitable? Cognition Therapeutics' return on equity of -150.93% beat Dogwood Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dogwood TherapeuticsN/A -217.12% -172.06% Cognition Therapeutics N/A -150.93%-100.82% Does the media refer more to DWTX or CGTX? In the previous week, Dogwood Therapeutics had 9 more articles in the media than Cognition Therapeutics. MarketBeat recorded 10 mentions for Dogwood Therapeutics and 1 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 1.87 beat Dogwood Therapeutics' score of 0.38 indicating that Cognition Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Dogwood Therapeutics Neutral Cognition Therapeutics Very Positive SummaryCognition Therapeutics beats Dogwood Therapeutics on 12 of the 15 factors compared between the two stocks. Remove Ads Get Dogwood Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DWTX vs. The Competition Export to ExcelMetricDogwood TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.97M$6.26B$5.29B$7.36BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-0.576.7221.6917.68Price / SalesN/A223.16371.6292.88Price / CashN/A65.6738.1534.64Price / Book0.765.776.373.94Net Income-$5.30M$142.23M$3.20B$247.45M7 Day Performance13.03%2.72%1.67%0.48%1 Month Performance-39.05%-14.04%-9.49%-7.08%1 Year PerformanceN/A-12.31%9.59%-0.35% Dogwood Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DWTXDogwood TherapeuticsN/A$3.73-10.3%N/AN/A$4.97MN/A-0.575Gap DownCGTXCognition Therapeutics3.1996 of 5 stars$0.35-2.0%$7.13+1,953.3%-79.9%$21.51MN/A-0.3620Gap DownFNCHFinch Therapeutics GroupN/A$13.16-2.5%N/A+492.4%$21.14M$110,000.00-1.49190Gap DownOVIDOvid Therapeutics4.4209 of 5 stars$0.29+2.2%$3.03+953.6%-91.1%$20.46M$566,000.00-0.6160LGVNLongeveron2.9947 of 5 stars$1.35-3.6%$8.67+542.0%-50.2%$20.15M$2.39M-0.2120Positive NewsGap UpPULMPulmatrix0.6185 of 5 stars$5.52+2.2%N/A+158.4%$20.15M$7.81M-2.0920Gap DownRVPHReviva Pharmaceuticals2.8623 of 5 stars$0.60+13.2%$10.00+1,566.7%-78.3%$20.07MN/A-0.545Upcoming EarningsPositive NewsGap DownMURAMural Oncology2.7341 of 5 stars$1.16+2.7%$13.00+1,020.7%-41.1%$19.98MN/A-0.13119Options VolumeNews CoverageNAIINatural Alternatives International1.5024 of 5 stars$3.12-5.7%N/A-57.2%$19.34M$121.85M-2.42290Short Interest ↓ENLVEnlivex Therapeutics3.3362 of 5 stars$0.89+0.2%$10.00+1,023.6%-31.4%$19.05MN/A-0.9170Short Interest ↓PMNProMIS Neurosciences3.1479 of 5 stars$0.58-5.1%$6.00+929.7%-72.8%$19.05MN/A-5.835Positive NewsGap Up Remove Ads Related Companies and Tools Related Companies CGTX Alternatives FNCH Alternatives OVID Alternatives LGVN Alternatives PULM Alternatives RVPH Alternatives MURA Alternatives NAII Alternatives ENLV Alternatives PMN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DWTX) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dogwood Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dogwood Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
